Durai et al. used receptor-ligand-and ligand-based VS to screen in-house libraries. They focused on the non-peptide TLR2 antagonists, distinct from several known inhibitors with fatty acid chains. For the receptor-ligand-based model, they prepared the protein-lipopeptide complex (PDB ID: 2Z7X) , while for the ligand-based model, they selected compounds from Guan et al. . The authors evaluated the best hits for their ability to bind directly to human recombinant TLR2. Furthermore, they tested the compounds' ability to inhibit the synthesis and secretion of IL-8 in human embryonic kidney cells overexpressing TLR2. Two molecules -C11 and C13 displayed both direct binding to TLR2 extracellular domain and reduced IL-8 production. The results supported the possibility that C11 and C13 can disrupt TLR2/1 heterodimerisation.